Delcath Systems, Inc. (DCTH)

NASDAQ: DCTH · IEX Real-Time Price · USD
4.950
-0.050 (-1.00%)
At close: Apr 12, 2024, 4:00 PM
5.01
+0.06 (1.21%)
After-hours: Apr 12, 2024, 7:41 PM EDT
-1.00%
Market Cap 121.59M
Revenue (ttm) 2.07M
Net Income (ttm) -47.68M
Shares Out 24.56M
EPS (ttm) -2.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 269,744
Open 4.990
Previous Close 5.000
Day's Range 4.850 - 5.000
52-Week Range 2.250 - 7.990
Beta 0.60
Analysts Strong Buy
Price Target 18.50 (+273.74%)
Earnings Date May 10, 2024

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1988
Employees 76
Stock Exchange NASDAQ
Ticker Symbol DCTH
Full Company Profile

Financial Performance

In 2023, DCTH's revenue was $2.07 million, a decrease of -24.05% compared to the previous year's $2.72 million. Losses were -$47.68 million, 30.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $18.5, which is an increase of 273.74% from the latest price.

Price Target
$18.5
(273.74% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK , April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...

10 days ago - PRNewsWire

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y. , March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional onc...

19 days ago - PRNewsWire

Delcath Systems Closes $7 Million Private Placement

NEW YORK, March 20, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the...

25 days ago - PRNewsWire

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

NEW YORK , March 19, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced to...

26 days ago - PRNewsWire

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...

27 days ago - PRNewsWire

Delcath Systems Announces $7 Million Private Placement

NEW YORK , March 15, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ...

4 weeks ago - PRNewsWire

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...

5 weeks ago - PRNewsWire

Delcath Systems to Participate in Upcoming Investor Conferences

NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

5 weeks ago - PRNewsWire

Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

7 weeks ago - PRNewsWire

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

NEW YORK , Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

2 months ago - PRNewsWire

Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

NEW YORK , Jan. 23, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

2 months ago - PRNewsWire

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™

NEW YORK , Jan. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

3 months ago - PRNewsWire

Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research

Retrospective Analysis of Changes in Patients with Metastatic Uveal Melanoma treated with Chemosat Hepatic Delivery System Results Support that Utilizing Delcath's HDS to Administer High-Dose Melphala...

4 months ago - PRNewsWire

Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK , Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer...

5 months ago - PRNewsWire

Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update

NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancer...

5 months ago - PRNewsWire

Delcath Systems to Host Third Quarter 2023 Results Call

NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced toda...

5 months ago - PRNewsWire

Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers

Retrospective Comparison of Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (17 and 9.9 months...

6 months ago - PRNewsWire

Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference

NEW YORK , Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tha...

6 months ago - PRNewsWire

Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023

NEW YORK , Oct. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participa...

6 months ago - PRNewsWire

A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

Independent Investigator Study Compared Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma  Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (516 ...

7 months ago - PRNewsWire

Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will particip...

7 months ago - PRNewsWire

Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

NEW YORK , Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tod...

8 months ago - PRNewsWire

Delcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

A Retrospective Comparative Study of SIRT and CS-PHP for Liver Targeted Therapy of Patients with Metastatic Uveal Melanoma NEW YORK , Aug. 29, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH)...

8 months ago - PRNewsWire

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delc...

8 months ago - PRNewsWire

Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers...

8 months ago - PRNewsWire